OP: "For those of you not aware, cyclazodone is a pemoline derivative (a defunct ADHD medicine not available in some parts of the world due to concerns over hepatotoxicity). I have never seen ec50's for the compound (in fact, i don't recall ever seeing ec50s for pemoline either), but it seems to be a not particularly noradrenergic monoamine releasing agent (with preference for DA release, and with what seems like serotonin release at high doses).
I bought some a few years ago, and only tested it a few times (stopping after finding it zombifying for whatever reason). Recently i've been giving it a second chance, and frankly like it quite abit. It is only euphoric in high doses, but has focus enhancing properties that rival amphetamine. Though not euphoric per say, it has profound antidepressant properties. Comedown is truly minimal, and the antidepressant lingers. Lacks the social awkwardness and anxiety of amphetamine, but being not particularly adrenergic, doesn't have the same motivation enhancement. It lasts a long time.
Doses have been in the 5 to 35mg range, primarily intranasal. It can induce physical anxiety, particularly at high doses and when unaccustomed to its effects, but these fades. It seems to be a very useful compound (wonder if my liver agrees with that)."
_____________________________________________________________________________________________________________________
Information pulled from psychonautwiki.org
N-Cyclopropylpemoline (also known as Cyclazodone) is a novel stimulant substance of the 4-oxazolidinone class. It is structurally related to pemoline and 4-methylaminorex. The mechanism of action involves promoting the release of dopamine and norepinephrine in the brain.
Cyclazodone was developed in the 1960s by the American Cyanamid Company. Its non-clinical use has only found recent attention as a research chemical study aid. It should be noted that the lack of pharmacological data and extremely limited history of human usage pose considerable concern regarding its long-term use as a substitute for prescription stimulants.
Subjective effects include stimulation, focus enhancement, stamina enhancement, increased blood pressure, and mild euphoria. Some anecdotal reports suggest that cyclazodone and its parent compound pemoline may have nootropic properties similar to central nervous system stimulants such as methylphenidate and amphetamine.
Cyclazodone has no documented history of recreational human usage before it appeared on the online research chemical market in 2017. Based on related compounds, it is speculated that it likely possesses hepatotoxic and other not-yet-known toxic properties.
According to patents filed by the inventors, cyclazodone exhibited central nervous system stimulating properties and anorexigenic properties much more potent than those of pemoline, and more potent than those of various other N-lower-alkyl-substituted pemoline derivatives. At the time cyclazodone also offered a much more favorable therapeutic index and margin of safety than pemoline and other N-lower-alkyl-substituted pemoline derivatives.
In animal models, cyclazodone exhibits central nervous system stimulant and antidepressant efficacy and potency at least equal to that of dextro-amphetamine. The duration of maximum activity spanned 180 minutes, and the total duration of excitation was in excess of 6 hours. Furthermore, according to the inventor's patents, cyclazodone also possessed anorexic efficacy and potency at least equal to that of dextro-amphetamine in animal models, yet the toxicity of cyclazodone was found to be low in comparison with the activity thereof.
- @deficiT
I bought some a few years ago, and only tested it a few times (stopping after finding it zombifying for whatever reason). Recently i've been giving it a second chance, and frankly like it quite abit. It is only euphoric in high doses, but has focus enhancing properties that rival amphetamine. Though not euphoric per say, it has profound antidepressant properties. Comedown is truly minimal, and the antidepressant lingers. Lacks the social awkwardness and anxiety of amphetamine, but being not particularly adrenergic, doesn't have the same motivation enhancement. It lasts a long time.
Doses have been in the 5 to 35mg range, primarily intranasal. It can induce physical anxiety, particularly at high doses and when unaccustomed to its effects, but these fades. It seems to be a very useful compound (wonder if my liver agrees with that)."
_____________________________________________________________________________________________________________________
Information pulled from psychonautwiki.org
N-Cyclopropylpemoline (also known as Cyclazodone) is a novel stimulant substance of the 4-oxazolidinone class. It is structurally related to pemoline and 4-methylaminorex. The mechanism of action involves promoting the release of dopamine and norepinephrine in the brain.
Cyclazodone was developed in the 1960s by the American Cyanamid Company. Its non-clinical use has only found recent attention as a research chemical study aid. It should be noted that the lack of pharmacological data and extremely limited history of human usage pose considerable concern regarding its long-term use as a substitute for prescription stimulants.
Subjective effects include stimulation, focus enhancement, stamina enhancement, increased blood pressure, and mild euphoria. Some anecdotal reports suggest that cyclazodone and its parent compound pemoline may have nootropic properties similar to central nervous system stimulants such as methylphenidate and amphetamine.
Cyclazodone has no documented history of recreational human usage before it appeared on the online research chemical market in 2017. Based on related compounds, it is speculated that it likely possesses hepatotoxic and other not-yet-known toxic properties.
Pharmacology
Cyclazodone is an approximately 3x - 5x more potent N-cyclopropyl derivative of pemoline. Pemoline is considered to be dopaminergic, but its precise method of action has not been fully determined. Pemoline has minimal affinity for noradrenaline receptors and thus has minimal sympathomimetic side effects compared with typical dopaminergic central nervous system stimulants such as methylphenidate and dextro-amphetamine.According to patents filed by the inventors, cyclazodone exhibited central nervous system stimulating properties and anorexigenic properties much more potent than those of pemoline, and more potent than those of various other N-lower-alkyl-substituted pemoline derivatives. At the time cyclazodone also offered a much more favorable therapeutic index and margin of safety than pemoline and other N-lower-alkyl-substituted pemoline derivatives.
In animal models, cyclazodone exhibits central nervous system stimulant and antidepressant efficacy and potency at least equal to that of dextro-amphetamine. The duration of maximum activity spanned 180 minutes, and the total duration of excitation was in excess of 6 hours. Furthermore, according to the inventor's patents, cyclazodone also possessed anorexic efficacy and potency at least equal to that of dextro-amphetamine in animal models, yet the toxicity of cyclazodone was found to be low in comparison with the activity thereof.
Duration | |
---|---|
Dosage | |
⇣ Oral | |
Threshold | 5 mg |
Light | 5 - 15 mg |
Common | 15 - 25 mg |
Strong | 25 - 40 mg |
Heavy | 40 mg +Liver damage may result from heavy or sustained usage. |
Total | 5 - 7 hours |
Onset | 20 - 45 minutes |
- @deficiT
Last edited by a moderator: